Investigation of COVID‐19 infection in patients with polymyalgia rheumatica during the predominance of the omicron variant DOI Creative Commons
Xinlei Ma,

Lanlan Xiao,

Jinzhi Wu

et al.

Rheumatology & autoimmunity, Journal Year: 2024, Volume and Issue: 4(3), P. 174 - 179

Published: May 27, 2024

Abstract Background Polymyalgia rheumatica (PMR) is an inflammatory disease that affects the older adult population. The aim of this study was to investigate risk and prognosis associated with coronavirus 2019 (COVID‐19) infection among patients diagnosed PMR during predominance Omicron variant. Methods In retrospective study, we included a cohort who met 2012 European League Against Rheumatism/American College Rheumatology classification criteria or 1982 diagnostic tracked their progress over time. diagnosis COVID‐19 based on clinical manifestations laboratory tests. We collected demographic information, activity, treatment data, data related COVID‐19. Results total, 101 were enrolled. Most exhibited low activity. Of total cohort, 81 (80.2%) categorized as individuals COVID‐19, while remaining 20 (19.8%) not Among 65 presence antigen, 16 tested positive for RNA. classified having mild (72, 88.9%). Two cases identified within confirmed infected group, resulting in recurrence rate 2.5% (2/81). Conversely, no relapses observed non‐infected group (0/20). our multivariate logistic regression analysis, found pre‐COVID‐19 activity independent factor (odds ratio = 30.00, 95% confidence interval: 2.137–421.117, p 0.012). Conclusion increased susceptibility may be influenced by pre‐existing PMR.

Language: Английский

Mechanistic considerations linking SARS-CoV-2 infection, inflammation, and the loss of immune tolerance DOI Creative Commons
Antonio Tonutti, Francesca Motta, Natasa Isailovic

et al.

Current Opinion in Immunology, Journal Year: 2025, Volume and Issue: 95, P. 102567 - 102567

Published: May 23, 2025

The immune response to SARS-CoV-2 has been implicated in the onset of multiple, seemingly unrelated, autoimmune diseases. also unmasking and/or production multiple autoantibodies, even absence clinical disease. Despite such data, it remains unclear whether antibodies targeting antiviral signaling proteins and mitochondrial antigens reflect bystander activation or alternatively contribute de novo viral escape mechanisms. With these comments mind, a variety professional antibody presenting cells including lung resident macrophages COVID-19 infected patients are impacted dependent on uptake antibody-opsonized virus by Fcγ receptors; yet infection is aborted via antibody-dependent effector mechanisms pyroptosis, possibly leading autoantibody production, autoinflammatory manifestations, respectively. TRIM21/Ro52, cytosolic E3-ubiquitin ligase with an Fc-gamma receptor domain, functions as intracytoplasmic receptor, directs complexes binding virions but autoantigens autophagy. During autophagy, Ig-virions-TRIM21/Ro52-autoantigens bind directly class II human leukocyte antigen lysosomal compartment, subsequent presentation cell surface. This process favors development specific humoral potential lead loss tolerance. Interestingly, TRIM21/Ro52 can pyroptosis. We propose that well-placed at crossroad between inflammatory autoimmunity.

Language: Английский

Citations

0
Are There Definite Disease Subsets in Polymyalgia Rheumatica? Suggestions from a Narrative Review DOI Open Access
Paolo Falsetti, Ciro Manzo, Marco Isetta

et al.

Healthcare, Journal Year: 2025, Volume and Issue: 13(11), P. 1226 - 1226

Published: May 23, 2025

Background: Polymyalgia rheumatica (PMR) has a multifaceted onset and course, making distinction between true PMR so-called “polymyalgic syndrome” (that is, similar manifestations caused by different conditions) is far from easy in clinical practice. The existence of subsets within may further complicate the diagnostic question. Distinguishing PMR-mimicking conditions does not just carry nomenclature value speculative significance. Indeed, correct diagnosis influences treatment, prognosis, epidemiological assessments, health policies. Objectives: We aimed to (1) ascertain presence definite peculiar subset/subgroup/cluster scientific literature; (2) describe any possible subset/cluster/subgroup identified at least two studies. Methods: performed non-systematic (PRISMA protocol followed) literature search on Embase Medline (OVID interface). following terms were used: polymyalgia rheumatica, subset, cluster, subgroup, subclinical giant cell arteritis, mimicking conditions, rheumatica-like immunotherapy, checkpoint inhibitor, acute-phase reactants or proteins, vaccination, infection, calcium pyrophosphate deposition disease chondrocalcinosis. Each paper’s reference list was scanned for additional publications meeting this study’s aim. Abstracts submitted conferences non-peer-reviewed sources included. Results: initial yielded 2492 papers, which 2389 articles excluded based title abstract screening. A total 103 underwent full-length review, 84 them finally assessed eligibility. seven large could be identified: with normal reactants; an infection trigger; (3) vaccination (4) arteritis (GCA); (5) (CPPD); (6) immune inhibitor (ICI) therapy; (7) clusters (based statistic clustering methods). Conclusions: baseline trigger categorized as disease. GCA most cases PMR/CPPD should mimickers. Finally, studies are required better categorize some emerging cluster analyses, ICI-induced PMR.

Language: Английский

Citations

0
Why is polymyalgia rheumatica a disease of older adults? Explanations through etiology and pathogenesis: a narrative review DOI
İlke Coşkun Benlidayı

Clinical Rheumatology, Journal Year: 2023, Volume and Issue: 43(3), P. 851 - 861

Published: July 20, 2023

Language: Английский

Citations

7
What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases DOI
Jin Kyun Park, Eun Bong Lee, Kevin Winthrop

et al.

Annals of the Rheumatic Diseases, Journal Year: 2024, Volume and Issue: 83(6), P. 687 - 695

Published: Feb. 27, 2024

Messenger RNA (mRNA) vaccines as a novel vaccine platform offer new tools to effectively combat both emerging and existing pathogens which were previously not possible. The 'plug play' feature of mRNA enables swift design production targeting complex antigens rapid incorporation constituents needed. This makes them likely be adopted for widespread clinical use in the future.Currently approved include only those against SARS-CoV-2 virus. These demonstrate robust immunogenicity substantial protection severe disease. Numerous viral are early late phase development. Several influenza tested trials, with some already 3 studies. Other phases development

Language: Английский

Citations

2
Common Non-Rheumatic Medical Conditions Mimicking Fibromyalgia: A Simple Framework for Differential Diagnosis DOI Creative Commons
Andrea D’Amuri, Salvatore Greco, Mauro Pagani

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(16), P. 1758 - 1758

Published: Aug. 13, 2024

Fibromyalgia (FM) is a chronic non-inflammatory disorder mainly characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and constellation of other symptoms. For this reason, delineating clear distinction between pure FM FM-like picture attributable to common diseases can be extremely challenging. Physicians must identify the most significant confounders in individual patients implement an appropriate diagnostic workflow, carefully choosing minimal (but sufficient) set tests used for identifying plausible specific case. This article discusses prevalent non-rheumatological conditions commonly observed general population that manifest with clinical features similar primary FM. Given their frequent inclusion differential diagnosis patients, focus will on elucidating distinctive characteristics each condition. Additionally, cost-effective efficient methodologies accurately discerning these examined.

Language: Английский

Citations

2
Safety, efficacy, and immunogenicity of SARS-CoV-2 mRNA vaccination in children and adult patients with rheumatic diseases: a comprehensive literature review DOI
Preeti Dhanasekaran,

Biraveena Thirunavuc Karasu,

Anselm Mak

et al.

Rheumatology International, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 22, 2024

Language: Английский

Citations

2
Secondary vasculitides DOI
Katharina Rose, Christof Iking‐Konert

Deleted Journal, Journal Year: 2024, Volume and Issue: 65(2), P. 129 - 136

Published: Jan. 24, 2024

Vaskulitiden, die im Rahmen anderer zugrunde liegender Erkrankungen auftreten, werden als sekundäre Vaskulitiden bezeichnet. In der breiten Differenzialdiagnostik ist eine Vielzahl sekundärer zu bedenken. Sekundäre sind gesamten Spektrum mit entsprechend vielfältiger klinischer Manifestation vertreten. Der vorliegende Beitrag bietet Übersicht von Systemerkrankungen und ätiologischen Faktoren, wie Infektionen, Medikamenten Malignomen, assoziiert sein können. Die Assoziationen infektiösen Erregern enorm breit gefächert können hier nur in Ansätzen aufgezeigt werden, ohne Anspruch auf Vollständigkeit schwerpunktmäßig aus westeuropäischer Perspektive. Insbesondere bei atypischen oder refraktären Verläufen empfiehlt sich Reevaluation einer sekundären Genese. Anbetracht Vielfalt an Differenzialdiagnosen besonderen Herausforderung interdisziplinäre Zusammenarbeit für korrekte frühzeitige Diagnose das therapeutische Management entscheidend. Im Vordergrund steht immer Therapie liegenden Erkrankung bzw. sofortige Beendigung Medikation Verdacht medikamenteninduzierte Vaskulitis.

Citations

1
Anti-OJ antibody-positive anti-synthetase syndrome following SARS-CoV-2 infection: a case report and literature review DOI Creative Commons

R. H. P. Sia,

Benjamin Massouridis,

Nicholas Ngan Kee

et al.

BMC Rheumatology, Journal Year: 2024, Volume and Issue: 8(1)

Published: Aug. 29, 2024

COVID-19 can induce a systemic inflammatory response with variable clinical manifestations. Similar to various viruses, has been implicated in the pathogenesis of autoimmune diseases. This article highlights potential for infections including SARS-CoV-2 virus exacerbations pre-existing diseases or even potentially unmask de novo particular anti-synthetase syndrome (ASSD) predisposed individuals. Although there are other case reports ASSD following infection, here we present first reported gentleman newly diagnosed anti-OJ positive infection.

Language: Английский

Citations

1
Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review DOI
Rada Mišković, Sara Radovic, Snežana Arandjelović

et al.

Rheumatology International, Journal Year: 2024, Volume and Issue: 44(11), P. 2621 - 2635

Published: Sept. 16, 2024

Language: Английский

Citations

1
Infective agents and polymyalgia rheumatica: key discussion points emerging from a narrative review of published literature DOI Creative Commons
Ciro Manzo, Marco Isetta, Alberto Castagna

et al.

Reumatologia/Rheumatology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 6, 2024

The aetiology of polymyalgia rheumatica (PMR) is unknown. Recently, reports on cases PMR following the coronavirus disease 2019 (COVID-19) have revived role infection as an aetiological or triggering factor. It estimated that patients with manifestations giant cell arteritis (GCA) in < 20% cases. To date, little known potential infectious agents facilitating this association. Given background, we performed a review published literature. Our first aim was to and discuss relationship between infective agents. Secondly, compared data PMR-only overlapping GCA seek any commonalities differences regarding type agent these two subgroups.

Language: Английский

Citations

1